Trial Profile
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2024 The protocol has been amended to remove the NHL cohort from the trial.
- 27 Feb 2024 Planned End Date changed from 1 Jun 2025 to 1 May 2026.
- 27 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.